Search Submit Your Manuscript

Become A Member

  1. Home
  2. February 2019
  3. 18. Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Non Responder Patients
Article Image
Admin

18. Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Non Responder Patients

Rahmanuddin, Shah Zeb, Muhammad Abbas and Fazal Rabbi

ABSTRACT

Objective: To evaluate the efficacy of sofosbuvir plus ribavirin in chronic hepatitis C genotype 3 interferon non responder patients.

Study Design: Prospective / observational study

Place and Duration of Study: This study was conducted at the Medical B Unit; Mardan Medical Complex, Mardan from Jan 2016 to December 2017.

Materials and Methods: Forty five adult eligible both male and female Hepatitis C genotype 3 patients non-responder to interferon were included in the study. Sofosbuvir 400mg and ribavirin on weight based daily for 24 weeks were given to patients. Patients were tested for absence of detectable HCV RNA by PCR at the end of treatment and 24 weeks after the completion of treatment to look for sustained virological response at 24 weeks.

Results: A total of forty five chronic Hepatitis C genotype 3 interferon non responder patients received treatment with sofosbuvir 400mg and ribavirin on weight basis for 24 weeks .All patients completed treatment. Out of forty five patients 19 (42.2%) were female and 26 (57.8%) were male. The average age of the patients included in the study was 45.6 years. Patients were classified on the basis of APRI score into two categories. In33 (73.3%) patients, the APRI score was <2 and in 12(26.7%) patients the APRI score was>2.Liver biopsy not done because it is an invasive procedure. The end of treatment response was 80 %( 36) while 20 %( 9) of the patients were non responder. The sustained virological response rate was 58.33 %( 21) while 41.67 % (15) patients were relapsed.

Conclusion: Combination of sofosbuvir and ribavirin for 24 weeks in chronic hepatitis C non responder patients was associated with low rate of sustained virological response at 24 weeks and high rate of relapse. This combination is not a good choice in those patients who has no response to peg interferon or conventional interferon.

Key Words: Chronic Hepatitis C, Sofosbuvir, Ribavirin

Citation of articles: Rahmanuddin, Zeb S, Abbas M, Rabbi F. Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Non Responder Patients. Med Forum 2019;30(2):72-74.